Rizatriptan

Limits on what this shows

• Key negative findings: The label's own data are indirect counter-evidence: hepatic injury is not a labeled adverse reaction, and only a pharmacokinetic (not toxicity) effect of hepatic impairment is described. A dedicated null-result search specific to this finding was not completed beyond the label review, due to session rate limiting.
• At-risk subgroups: None established at approved human dosing; this is a preclinical, mechanistic-tier signal only.

Regulatory status

Not addressed in the label; hepatic injury is not listed as a labeled adverse reaction, and hepatic-impairment language in the label concerns clearance in patients with pre-existing liver disease, not rizatriptan-induced liver injury.

Population evidence

Tier B: an in vitro/animal hepatotoxicity study naming rizatriptan specifically in the title and design ("Triazole rizatriptan Induces Liver Toxicity through Lysosomal/Mitochondrial Dysfunction"), published in Drug Research, 2016. This is a rizatriptan-specific study, distinct from the sumatriptan-specific NAC/taurine hepatoprotection study cited in the companion sumatriptan dossier, though both trace to overlapping authors at the same pharmacology group, who appear to have studied several triptans as individual drug-specific projects rather than issuing one class-wide claim. Full model details (species/cell system, rizatriptan concentration or dose, exact biomarkers) could not be independently confirmed from sources accessible this session: the direct PubMed record page returned a bot-verification interstitial, Crossref metadata omitted the abstract, and an Unpaywall check confirmed the article is not open access with no repository copy available. This is disclosed as a citation-completeness limitation, not an asserted detail.

Mechanism

Named in the study's own framing: lysosomal and mitochondrial dysfunction as the route to rizatriptan-induced liver injury, with CYP450 activity implicated in the associated oxidative stress and cytotoxicity (see Oxidative stress entry and Overlap map).

Counter-evidence held on record

Preclinical and mechanistic only; do not present as an established human mitochondrial-toxicity risk from approved rizatriptan dosing. No mitochondrial-support supplementation (CoQ10, carnitine, or similar) is indicated on this basis, and rizatriptan's acute, as-needed dosing pattern further limits any cumulative burden compared with a medication taken daily.

Limits on what this shows

• Key negative findings: None identified beyond the label's absence of a hepatotoxicity or oxidative-stress adverse-reaction listing; a dedicated null-result search was not completed beyond the label and the located study, due to session rate limiting.
• At-risk subgroups: None established at approved human dosing; preclinical, mechanistic-tier signal only.

Regulatory status

Not addressed in the label as an oxidative-stress finding.

Population evidence

Tier B: same in vitro/animal study as the Mitochondrial burden entry above (Drug Research, 2016); the search-listing summary explicitly states "CYP450 is involved in rizatriptan-induced oxidative stress and cytotoxicity." As with the Mitochondrial burden entry, full quantitative detail (ROS levels, glutathione, lipid peroxidation markers) could not be independently confirmed this session; see that entry's access note, which applies identically here (see Overlap map).

Mechanism

Named: CYP450-dependent generation of oxidative stress contributing to rizatriptan's hepatocellular cytotoxicity in the model system studied.

Counter-evidence held on record

Graded yellow on the strength of a single rizatriptan-specific preclinical study; treat this and the Mitochondrial burden entry as one underlying source viewed from two required-category angles, not two independent confirmations (see Overlap map). No antioxidant supplementation is indicated on this basis.

Limits on what this shows

• Why no grade: Both Step 7 conditions are met: no Tier B or C evidence and no circulating claim. Assessment: genuine gap, reconfirmed on a completed PubMed zero-result query and a completed, explicitly irrelevant Crossref result set, with a tooling-limited component still present (three literature channels remained inaccessible on fresh attempt this pass). Mechanistically, rizatriptan's MAO-A-dominated first-pass metabolism is not a copper-dependent pathway, which further reduces prior plausibility for this category. A later revision should re-attempt Europe PMC, Semantic Scholar, and OpenAlex specifically for this category once that policy block lifts.

Channels tried

FDA prescribing information, reviewed as a full-text search this pass, not only the Clinical Pharmacology excerpt (no mention of copper or ceruloplasmin anywhere in the document, including Adverse Reactions); PubMed search-listing, query "rizatriptan copper" (zero results, explicit "No results were found," reconfirmed fresh this pass); Crossref API bibliographic query "rizatriptan copper ceruloplasmin" (completed fresh this pass; 10 results reviewed, nine unrelated copper/ceruloplasmin biochemistry papers and one non-study rizatriptan USP reference-standard monograph, no actual study pairing the two).

Channels blocked

Europe PMC, Semantic Scholar API, and OpenAlex API were re-attempted fresh this pass and were all still blocked: Europe PMC and OpenAlex returned HTTP 403 policy-denial connection rejections confirmed directly against the live proxy status log, and Semantic Scholar returned repeated HTTP 429 responses. This is a persistent, organization-level block, not a single blocked attempt; OpenAlex's per-DOI single-record lookup fallback does not apply here since no specific candidate paper exists to check for this category.

Circulating claim

None found. A consumer drug-interaction database check (see Fails verification) found no nutrient- or copper-related claims listed for rizatriptan.

Limits on what this shows

• Why no grade: Both Step 7 conditions are met: no Tier B or C evidence and no circulating claim. Assessment: mostly a genuine gap, now stronger than the original review's: the direct "rizatriptan iron" query, the two corrected sub-terms "rizatriptan anemia" and "rizatriptan hematocrit," and the Crossref cross-check were all clean, completed negatives. A residual tooling-limited component remains, narrower than before: only the "rizatriptan hemoglobin" PubMed sub-term and the three blocked API channels stayed unresolved this pass. Rizatriptan's high oral bioavailability (about 45%) and lack of documented mucosal or transporter-mediated absorption interference further reduce prior plausibility. A later revision should re-attempt the "rizatriptan hemoglobin" PubMed query specifically, along with Europe PMC, Semantic Scholar, and OpenAlex.

Channels tried

FDA prescribing information, reviewed as a full-text search this pass (no mention of iron, hemoglobin, hematocrit, or anemia anywhere in the document, and no hematologic laboratory abnormalities in Adverse Reactions or postmarketing sections); PubMed search-listing, original query "rizatriptan iron" (zero results, reconfirmed); the originally broken combined query was split into three corrected single-term PubMed searches this pass: "rizatriptan anemia" (zero results, explicit "No results were found") and "rizatriptan hematocrit" (zero results, explicit "No results were found") both completed cleanly; "rizatriptan hemoglobin" could not be completed after four separately-paced attempts across the session (two returned a bot-verification interstitial, two returned an incomplete/empty page fetch), a distinct failure mode from the original broken OR-logic and still unresolved. A fresh Crossref API bibliographic query ("rizatriptan iron hemoglobin anemia") also completed this pass: all 10 reviewed results were general hematology literature with no rizatriptan or triptan-class mention at all, a further negative data point.

Channels blocked

Europe PMC, Semantic Scholar API, and OpenAlex API were re-attempted fresh this pass and were still blocked (HTTP 403 policy-denial confirmed against the live proxy status log for Europe PMC and OpenAlex; HTTP 429 for Semantic Scholar). OpenAlex's per-DOI single-record lookup fallback does not apply, since no specific candidate paper exists to check for this category.

Circulating claim

None found; see Fails verification for the consumer-database check.

Limits on what this shows

• Why no grade: Both Step 7 conditions are met: no Tier B or C evidence and no circulating claim. Assessment: a genuine gap, now confirmed by two independent completed negative searches (PubMed and Crossref) rather than one, with a residual tooling-limited component (three API channels still blocked, one supplementary Crossref re-check not completed). Oral tablets and orally disintegrating tablets do transit the gastrointestinal tract, but no antimicrobial or motility mechanism is documented, and rizatriptan's acute, as-needed dosing pattern further limits plausibility of a sustained microbiome effect compared with a chronic daily medication.

Channels tried

The originally planned PubMed query, not completed in the first review, was run this pass: "rizatriptan AND (microbiome OR microbiota OR gut flora)" completed cleanly with zero results, explicit "No results were found" (meta-log_resultcount: 0). Crossref API, query combining rizatriptan with gut microbiome terms (from the original review), which completed and returned only unrelated general microbiome research with no connection to rizatriptan or any migraine drug (explicit negative). FDA label reviewed as a full-text search this pass for any documented antimicrobial, pH-altering, or motility-disrupting mechanism, or any mention of microbiome, microbiota, intestinal flora, or gastrointestinal flora (none found anywhere in the document).

Channels blocked

Europe PMC, Semantic Scholar API, and OpenAlex API were re-attempted fresh this pass and remained blocked (HTTP 403 policy-denial confirmed against the live proxy status log for Europe PMC and OpenAlex; HTTP 429 for Semantic Scholar). A fresh Crossref re-check specific to this category ("rizatriptan gut microbiome microbiota") was attempted this pass and hit proxy-level rate limiting (HTTP 429) before completing; it was not retried further since the PubMed query above and the original review's Crossref query already provide two independent completed negatives for this category.

Circulating claim

None found; see Fails verification for the consumer-database check.

Limits on what this shows

• Key negative findings: Gori et al., 2005 found no change in cerebral blood flow velocity with rizatriptan during migraine attacks, directly bounding the magnitude of any vasoconstrictive effect in at least one vascular territory.
• At-risk subgroups: Patients with known vasospastic or coronary artery disease, per class-wide cardiac-safety contraindications (a cardiac-safety concern, not a nutrient-status one); rare published case reports describe renal infarction temporally associated with rizatriptan use (see Monitoring panel), a clinical vasospasm outcome, not a nutrient deficiency, per Hard Rule 2.

Regulatory status

Not labeled as an oxygen-delivery effect; the label carries general cardiac and non-coronary vasospasm warnings common to the triptan class, and separate published case reports (not part of this grading; see Monitoring panel) describe renal infarction during rizatriptan use.

Population evidence

Tier A: Tfelt-Hansen P, Seidelin K, Stepanavage M, Lines C. Double-blind, placebo-controlled, crossover study in 16 normal male subjects, comparing oral rizatriptan 10 mg, intravenous ergotamine, their combination, and placebo, with strain-gauge plethysmography of peripheral (hand and forearm) blood flow over 8 hours. Br J Clin Pharmacol, 2002. Rizatriptan produced "only a small transient vasoconstrictor effect" and, combined with ergotamine, "no additional effect on ergotamine-induced constriction." A second rizatriptan-specific Tier A study (Gori et al., 2005) found rizatriptan "does not change cerebral blood flow velocity during migraine attacks," a directly relevant null/counter-evidence finding for a different vascular bed.

Mechanism

Named and explicit: 5-HT1B/1D-receptor-mediated peripheral vasoconstriction, the drug's own intended pharmacologic action expressed peripherally, described in the source itself as small and transient rather than sustained.

Counter-evidence held on record

This is rizatriptan's own intended vasoconstrictive mechanism, described in its own dedicated study as small and transient, not anemia, hypoxia, or a nutrient-mediated oxygen-carrying deficiency. It tracks rizatriptan's 2- to 3-hour elimination half-life and is expected to resolve between doses given the acute, as-needed dosing pattern. No iron, B12, or other hematologic supplementation is indicated by this finding.

Limits on what this shows

• Key negative findings: No rizatriptan-specific energy-metabolism study, positive or negative, was located to confirm or refute the extrapolation either way.
• At-risk subgroups: Not established for rizatriptan specifically.

Regulatory status

Not addressed in the label as an energy-metabolism effect.

Population evidence

Tier C, class extrapolation: Boska MD, Welch KM, Schultz L, Nelson J. Effects of the anti-migraine drug sumatriptan on muscle energy metabolism: relationship to side-effects. Cephalalgia, 2000. This is the same human 31P-MRS study cited under ATP production in the companion sumatriptan dossier; rizatriptan was not in that studied cohort. Targeted Crossref queries combining rizatriptan with ATP, mitochondrial energy, and muscle energy-metabolism terms returned no rizatriptan-specific result (confirmed negative, this session).

Mechanism

Extrapolated only: if rizatriptan's peripheral vasoconstriction were to reduce local muscle perfusion as sumatriptan's does, a similar transient muscle energy-metabolism signal could theoretically follow. This is not confirmed for rizatriptan; the one rizatriptan-specific vasoconstriction study available (Tfelt-Hansen 2002, see Oxygen delivery/utilization) found a materially smaller, transient effect than sumatriptan's own vasoconstrictive profile, which weakens rather than strengthens this extrapolation.

Counter-evidence held on record

This entry exists to satisfy the mandatory seven-category review and to make the class-extrapolation explicit, not because rizatriptan itself has been shown to affect ATP production. Do not present this as rizatriptan-specific evidence. No energy-support supplementation (CoQ10, carnitine, creatine, or similar) is indicated on this basis.